Evidence
Alzheimers Dement. 2024 Feb 7. doi: 10.1002/alz.13658. Online ahead of print.
ABSTRACT
INTRODUCTION: Lewy body disease, a frequently observed co-pathology in Alzheimer’s disease (AD), can be identified antemortem in cerebrospinal fluid (CSF) by α-synuclein seed amplification assay (αS-SAA). The prevalence and clinical impact of CSF αS-SAA positivity in AD are still unknown.
METHODS: αS-SAA was performed on CSF samples from 240 AD patients (preclinical, prodromal, and dementia stages), 85 controls, 84 patients with Parkinson’s disease (PD), and 21 patients with PD with dementia or dementia with Lewy bodies. In AD patients, associations between αS-SAA positivity and cognitive changes were also evaluated.
RESULTS: In agreement with available neuropathological studies, αS-SAA positivity was observed in 30% of AD patients (vs 9% in controls), and was associated with cognitive decline, visuospatial impairment, and behavioral disturbances.
DISCUSSION: αS-SAA positivity in AD patients reflects the prevalence observed in neuropathological series and is associated with a worse clinical outcome. These data confirm the validity of CSF αS-SAA positivity as biomarker of synucleinopathy.
PMID:38323747 | DOI:10.1002/alz.13658
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay
🌐 90 Days
VR Related Evidence Matrix
- a-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
- Detection of a-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder
- Detection of a-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder
- Detecting Misfolded a-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- The Body, the Brain, the Environment, and Parkinson's Disease
- Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease
- Enhanced Spine Stability and Survival Lead to Increases in Dendritic Spine Density as an Early Response to Local Alpha-Synuclein Overexpression in Mouse Prefrontal Cortex
- Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits
- Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Influences of amyloid-beta and tau on white matter neurite alterations in dementia with Lewy bodies
- Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
- Conjugal Synucleinopathies: A Clinicopathologic Study
- Conjugal Synucleinopathies: A Clinicopathologic Study
- Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Automatic classification of AD pathology in FTD phenotypes using natural speech
- CSF pulsations measured in Parkinson's disease patients using EPI-based fMRI data
- CSF pulsations measured in Parkinson's disease patients using EPI-based fMRI data
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- The Relationship of Cerebrospinal Fluid Biomarkers and Cognitive Performance in Frontotemporal Dementia
- Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change
- Adaptive immune changes associate with clinical progression of Alzheimer's disease
- Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19
- The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer's Disease: A Pragmatic Review for Clinicians
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Cerebrospinal fluid shunt surgery reduces the risk of developing dementia and Alzheimer's disease in patients with idiopathic normal pressure hydrocephalus: a nationwide population-based propensity-weighted cohort study
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Machine learning prediction of future amyloid beta positivity in amyloid-negative individuals
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- Latest advances in mechanisms of epileptic activity in Alzheimer's disease and dementia with Lewy Bodies
- miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach
- Sequencing of cerebrospinal fluid cell-free DNA facilitated early differential diagnosis of intramedullary spinal cord tumors
- Neuroinflammation is associated with Alzheimer's disease co-pathology in dementia with Lewy bodies
- Association of CSF biomarkers with MRI brain changes in Alzheimer's disease
- Clinical value of Alzheimer's disease biomarker testing
- Clinical value of Alzheimer's disease biomarker testing
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- Association of Parkinson's disease to Parkinson's plus syndromes, Lewy body dementia, and Alzheimer's dementia
- Cathepsin L prevents the accumulation of alpha-synuclein fibrils in the cell
- Skin Biopsy Detection of Phosphorylated a-Synuclein in Patients With Synucleinopathies
- Reduced cardiac 123I-MIBG uptake is a robust biomarker of Lewy body disease in isolated rapid eye movement sleep behaviour disorder
- Identifying Mixed Dementia With Lewy Bodies and Alzheimer Disease Using Multitracer PET Imaging: A Case Study
- Identification of DAGLA as an autoantibody target in cerebellar ataxia
- Patient- and proxy-reported quality of life in advanced dementia with Lewy bodies
- Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
- Altered TFEB subcellular localization in nigral neurons of subjects with incidental, sporadic and GBA-related Lewy body diseases
- Disease and brain region specific immune response profiles in neurodegenerative diseases with pure and mixed protein pathologies
Evidence Blueprint
Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Investigating alpha-synuclein co-pathology in Alzheimer’s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay
🌐 365 Days
VR Related Evidence Matrix
- a-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
- Detection of a-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder
- Detection of a-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder
- Detecting Misfolded a-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease
- Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer's disease
- Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies
- Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- Toward the quantification of α-synuclein aggregates with digital seed amplification assays
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
- A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
- Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease
- CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
- Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly
- The Body, the Brain, the Environment, and Parkinson's Disease
- Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer's disease
- Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy
- Prevalence, distribution, and severity of cerebral amyloid angiopathy differ between Lewy body diseases and Alzheimer's disease
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease
- Enhanced Spine Stability and Survival Lead to Increases in Dendritic Spine Density as an Early Response to Local Alpha-Synuclein Overexpression in Mouse Prefrontal Cortex
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits
- Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia
- LRP10 and α-synuclein transmission in Lewy body diseases
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- Galectin-3 is upregulated in frontotemporal dementia patients with subtype specificity
- Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue
- Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer's Disease Regardless of Concomitant Small Vessel Disease
- CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Reduced cerebrospinal fluid motion in patients with Parkinson's disease revealed by magnetic resonance imaging with low b-value diffusion weighted imaging
- Mitochondrial DNA deletions in the cerebrospinal fluid of patients with idiopathic REM sleep behaviour disorder
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Alpha-synuclein fibrils amplified from multiple system atrophy and Parkinson's disease patient brain spread after intracerebral injection into mouse brain
- Longitudinal motor decline in dementia with Lewy bodies, Parkinson disease dementia, and Alzheimer's dementia in a community autopsy cohort
- Influences of amyloid-beta and tau on white matter neurite alterations in dementia with Lewy bodies
- Morphological characteristics differentiate dementia with Lewy bodies from Parkinson disease with and without dementia
- Lewy body pathology modifies risk factors for cerebral amyloid angiopathy when comorbid with Alzheimer's disease pathology
- Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden
- Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease
- Impact of incidental synucleinopathy in mild cognitive impairment due to Alzheimer disease
- Conjugal Synucleinopathies: A Clinicopathologic Study
- Conjugal Synucleinopathies: A Clinicopathologic Study
- Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson's disease
- Profiling amyloid-β peptides as biomarkers for cerebral amyloid angiopathy
- Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Early onset diagnosis in Alzheimer's disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
- Automatic classification of AD pathology in FTD phenotypes using natural speech
- CSF pulsations measured in Parkinson's disease patients using EPI-based fMRI data
- CSF pulsations measured in Parkinson's disease patients using EPI-based fMRI data
- Astrocytes and Alpha-Synuclein: Friend or Foe?
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
- Decreased DHA-containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble Aβ42 , phosphorylated α-synuclein, and synaptopathology
- Glymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Associations between cardiometabolic multimorbidity and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study